自2021年1月1日起，美国医疗保险与医疗补助服务中心要求美国医院公开披露其提供的服务价格。我们分析了有关前列腺癌相关服务的价格公示。截至2022年5月，对所有美国医院进行了查询，包括前列腺特异抗原总量和游离状态、前列腺磁共振成像、前列腺活检、根治性前列腺切除术和调强放射治疗的公开披露价格。价格根据地区价格平价进行调整。将揭示价格的医院与未揭示价格的医院进行比较。在6013家医院中，3840家（64%）揭示了至少一项前列腺癌相关服务的定价。与未揭示价格的医院相比，揭示价格的医院具有更高的年度总收入中位数（318,502,426美元与62,930,436美元，P < 0.001）以及更大的非营利机构比例（56% vs 30%，P < 0.001）、学术关联（46% vs 13%，P < 0.001）和低医院密度社区（68% vs 62%，P < 0.001）。除前列腺活检外，所有服务的自费价格均高于保险协商价格（P < 0.001）。自费前列腺切除术的价格范围最大，90th至10th百分位之间相差32倍（47,445美元至1,476美元）。学术性和营利性医院、年度总收入最高的医院的自费前列腺特异抗原、磁共振成像、活检、调强放射治疗和前列腺切除术的价格均高于非学术性、非营利性医院以及年度总收入第三和第四四分位数的医院（P < 0.01）。自费前列腺活检和前列腺切除术的价格在城市社区中和医院密度高的社区中更高（P < 0.001）。自费前列腺癌服务的价格通常高于保险协商价格，并且在营利性医院、学术医院和年度总收入最高的医院更高。更高的社区医院密度与价格披露的可能性不相关，也不会降低服务价格，这表明当地竞争不会导致价格下降，并可能削弱价格披露的动力。 ©2023. 作者（们），在Springer Nature Limited独家许可下。

Starting January 1, 2021, Centers for Medicare and Medicaid Services required United States hospitals to publicly disclose prices of their services provided. We analyzed publicly-disclosed prices of prostate cancer-related services.All United States hospitals were queried for publicly-disclosed prices of total and free prostate-specific antigen, prostate magnetic resonance imaging, prostate biopsy, radical prostatectomy, and intensity-modulated radiation therapy as of May 2022. Prices were adjusted by regional price parity. Hospitals disclosing prices were compared with non-disclosing hospitals.Of 6013 hospitals, 3840 (64%) disclosed pricing for at least one prostate cancer-related service. Compared to non-disclosing hospitals, disclosing hospitals had higher median gross annual revenue ($318,502,426 vs. $62,930,436, p < 0.001) and were more likely to be non-profit (56% vs. 30%, p < 0.001), academic-affiliated (46% vs. 13%, p < 0.001), and in neighborhoods with low hospital density (68% vs 62%, p < 0.001). Self-pay prices were higher than insurance-negotiated prices for all services (p < 0.001) other than prostate biopsy. The range of pricing was widest for self-pay prostatectomy, with a 32-fold difference from 90th to 10th percentile ($47,445 to $1476). Self-pay prices of total prostate-specific antigen, magnetic resonance imaging, biopsy, intensity-modulated radiation therapy, and prostatectomy were higher at academic vs. non-academic, for-profit vs. non-profit hospitals, and hospitals in the top quartile of gross annual revenue vs. the third and fourth quartiles (p < 0.01). Self-pay prices of prostate biopsy and prostatectomy were higher in urban vs. rural neighborhoods and neighborhoods with high vs. low hospital density (p < 0.001).Self-pay prices of prostate cancer services were generally higher than insurance-negotiated prices and were higher at for-profit hospitals, academic hospitals, and hospitals in the highest quartile of gross annual revenue. Higher neighborhood hospital density was not associated with higher likelihood of price disclosure nor lower pricing of services, suggesting that local competition does not lead to lower prices and may disincentivize disclosure of prices.© 2023. The Author(s), under exclusive licence to Springer Nature Limited.